ARGX compared with ALNY: revenue, margins and what each company keeps, and the suppliers and customers both name

ARGXArgenx SE

Mkt capRevenueRevenue

ALNYAlnylam Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

ARGXArgenx SE

ALNYAlnylam Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARGX1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Oct 22 '26±8.8%▼−1.61%×0.18

ALNY

1 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±11.1%▼−25.13%×2.26

Q2 FY26—▼−28.31%—

= impliedARGX realized, solidALNY realized, hatchedOne scale, both sides: full bar = 29%× = |realized| ÷ impliedSource: market data

Q1 FY26

—

▲+2.76%

—

Feb 12 '26—▼−4.28%—

ARGXArgenx SE

893.85▼−0.45%· post 895.00

Mkt cap$55.3BRevenue—Revenue—

ALNYAlnylam Pharmaceuticals, Inc.

164.89▼−5.24%· post 165.53

ClosedOct 30 '26

Mkt cap$22.1BRevenue$1.5BQ3 FY26Revenue$3.7BFY25

Compare

ClosedOct 30 '26

ARGXArgenx SE

ALNYAlnylam Pharmaceuticals, Inc.

893.85▼−0.45%post 895.00

Price

164.89▼−5.24%post 165.53

$55.3B

Mkt cap

$22.1B

—

Revenue

$1.5BQ3 FY26

—

Revenue

$3.7BFY25

ARGX893.85▼−0.45%vsALNY164.89▼−5.24%ClosedOct 30 '26